title: Tuberculous monoarthritis after treatment with adalimumab in Crohn's disease.
authors.forename: Alejandro
authors.initials: A
authors.lastname: Martínez-Caselles
authors.forename: Cristina
authors.initials: C
authors.lastname: Martínez-Pascual
authors.forename: María
authors.initials: M
authors.lastname: Muñoz-Tornero
authors.forename: Antonio
authors.initials: A
authors.lastname: Sánchez-Torres
authors.forename: Fernando
authors.initials: F
authors.lastname: Carballo-Álvarez
mesh_terms: D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy* / Q000382:microbiology; D001170:Arthritis, Infectious / Q000209:etiology* / Q000382:microbiology; D003424:Crohn Disease / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis; D014391:Tuberculosis, Miliary / Q000473:pathology; D014394:Tuberculosis, Osteoarticular / Q000209:etiology* / Q000382:microbiology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000068879:Adalimumab